# EDGAR Filing Document

**Accession Number:** 0000898437
**File Stem:** 0001171843-25-007033
**Filing Date:** 2025-11
**Character Count:** 18496
**Document Hash:** f8d024f0b0ca7c2eb1768dccfa163186
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-007033.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001171843-25-007033

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**EFFECTIVENESS DATE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anika Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000898437
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043145961
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291282
- **FILM NUMBER:** 251453729

**BUSINESS ADDRESS:**
- **STREET 1:** 32 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** (781) 457-9000

**MAIL ADDRESS:**
- **STREET 1:** 32 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANIKA THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19970114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANIKA RESEARCH INC
- **DATE OF NAME CHANGE:** 19930309

**As filed with the Securities and Exchange Commission on November 5, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Anika Therapeutics, Inc.**

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| **Delaware** | **04-3145961** |
| *(State or other jurisdiction of* | *(I.R.S. Employer Identification No.* |
| *incorporation or organization)* |  |
| **32 Wiggins Avenue** |  |
| **Bedford, Massachusetts** | **01730** |
| *(Address of principal executive offices)* | *(Zip code)* |

---

**Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan**

*(Full title of the plan)*

**Cheryl R. Blanchard**

**President and Chief Executive Officer**

**Anika Therapeutics, Inc.**

**32 Wiggins Avenue**

**Bedford, Massachusetts 01730**

**(781) 457-9000**

*(Name, address, including zip code, and telephone number, including area code, of agent for service)*

*With copies to:*

---

| | |
|:---|:---|
| **Michael H. Bison** | **David Colleran** |
| **Goodwin Procter LLP** | **Anika Therapeutics, Inc.** |
| **100 Northern Avenue** | **32 Wiggins Avenue** |
| **Boston, MA 02110** | **Bedford, MA 01730** |
| **(617) 570-1933** | **(781) 457-9261** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☒ <br> Non-accelerated filer ☐ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**STATEMENT OF INCORPORATION BY REFERENCE**

This Registration Statement on Form S-8 registers 475,000 additional shares of the Registrant's common stock, $0.01 par value per share ("Common Stock"), to be issued under the Registrant's 2017 Omnibus Incentive Plan, as amended (the "Plan"). The additional shares represent an increase in the number of shares of Common Stock reserved for issuance under the Plan, which increase was previously approved by the Registrant's Board of Directors and subsequently approved by the Registrant's stockholders on June 20, 2025, at the Registrant's 2025 Annual Meeting of Stockholders.

The additional shares described above are of the same class as other securities relating to the Plan for which the Registrant previously filed a registration statements on Form S-8 with the U.S. Securities and Exchange Commission (the "Commission") on [July 7, 2017](https://www.sec.gov/Archives/edgar/data/898437/000117184317003996/0001171843-17-003996-index.htm) (File No. 333-219190), [June 21, 2019](https://www.sec.gov/Archives/edgar/data/898437/000117184319004107/0001171843-19-004107-index.htm) (File No. 333-232254), [June 19, 2020](https://www.sec.gov/Archives/edgar/data/898437/000117184320004454/0001171843-20-004454-index.htm) (File No. 333-239304), [August 6, 2021](https://www.sec.gov/Archives/edgar/data/898437/000117184321005595/0001171843-21-005595-index.htm) (File No. 333-258529), [August 5, 2022](https://www.sec.gov/Archives/edgar/data/898437/000117184322005377/0001171843-22-005377-index.htm) (File No. 333-266550), and [August 8, 2023](https://www.sec.gov/Archives/edgar/data/898437/000117184323005115/0001171843-23-005115-index.htm) (File No. 333-273812) (together, the "Prior Registration Statements"). The information contained in the Prior Registration Statements, as filed with the Commission, is hereby incorporated by reference pursuant to General Instruction E to Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/898437/000117184318004486/exh_31.htm) | [Certificate of Incorporation of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 6, 2018)](https://www.sec.gov/Archives/edgar/data/898437/000117184318004486/exh_31.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/898437/000117184318004486/exh_32.htm) | [Bylaws of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on June 6, 2018)](https://www.sec.gov/Archives/edgar/data/898437/000117184318004486/exh_32.htm) |
| [5.1](exh_51.htm) | [Opinion of Goodwin Procter LLP](exh_51.htm) |
| [23.1](exh_231.htm) | [Consent of Deloitte & Touche LLP](exh_231.htm) |
| [23.2](exh_51.htm) | [Consent of Goodwin Procter LLP (included in Exhibit 5.1)](exh_51.htm) |
| [24.1](#poa) | [Power of Attorney (included on the signature page of this registration statement)](#poa) |
| [99.1](https://www.sec.gov/ix?doc=/Archives/edgar/data/898437/000117184325004062/f8k_062425.htm) | [Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended on June 18, 2019, June 16, 2020, June 16, 2021, June 8, 2022, June 14, 2023, and June 20, 2025) (incorporated by reference to Exhibit 10.1 on the Current Report on Form 8-K filed on June 24, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/898437/000117184325004062/f8k_062425.htm) |
| [107](exh_107.htm) | [Filing Fee Table](exh_107.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, Commonwealth of Massachusetts, as of November 5, 2025.

---

| |
|:---|
| **ANIKA THERAPEUTICS, INC.** |
| /s/ Cheryl R. Blanchard |
| Cheryl R. Blanchard |
| President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Cheryl R. Blanchard and David Colleran, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments and any registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act of 1933 to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| <br> <u>/s/ Cheryl R. Blanchard</u><br> Cheryl R. Blanchard<br>| <br> Chief Executive Officer, President and Director<br> *(Principal Executive Officer)*<br>| <br>November 5, 2025<br>|
| <br> <u>/s/ Stephen D. Griffin</u><br> Stephen D. Griffin<br>| <br>Chief Financial Officer and Chief Operating Officer<br> *(Principal Financial Officer)*<br>| <br>November 5, 2025<br>|
| <br> <u>/s/ Ian McLeod</u><br> Ian McLeod<br>| <br>Vice President, Chief Accounting Officer and Treasurer<br> *(Principal Accounting Officer)*<br>| <br>November 5, 2025<br>|
| <br> <u>/s/ John B. Henneman, III</u><br> John B. Henneman, III<br>| <br>Director and Chair of the Board of Directors<br>| <br>November 5, 2025<br>|
| <br> <u>/s/ Joseph H. Capper</u><br>Joseph H. Capper<br>| <br>Director<br>| <br>November 5, 2025<br>|
| <br> <u>/s/ Sheryl L. Conley</u><br> Sheryl L. Conley<br>| <br>Director<br>| <br>November 5, 2025<br>|
| <br> <u>/s/ Gary P. Fischetti</u><br> Gary P. Fischetti<br>| <br> Director<br>| <br> November 5, 2025<br>|
|  <br><u>/s/ William R. Jellison</u><br> William R. Jellison<br>| <br> Director<br>| <br> November 5, 2025<br>|
| <br> <u>/s/ Glenn R. Larsen</u><br> Glenn R. Larsen<br>| <br> Director<br>| <br> November 5, 2025<br>|
| <br> <u>/s/ Stephen O. Richard</u><br> Stephen O. Richard<br>| <br> Director<br>| <br> November 5, 2025<br>|
| <br> <u>/s/ Susan L. N. Vogt</u><br> Susan L. N. Vogt<br>| <br> Director<br>| <br> November 5, 2025<br>|

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| <br>![](goodwinlogo.jpg)<br>| Goodwin Procter llp<br> 100 Northern Avenue<br> Boston, MA 02210<br>goodwinlaw.com<br> +1 617 570 1000 |

---

November 5, 2025

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, Massachusetts 01730

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 475,000 shares (the "Shares") of Common Stock, $0.01 par value per share ("Common Stock"), of Anika Therapeutics, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2017 Omnibus Incentive Plan, as amended (the "Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ GOODWIN PROCTER LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated March 14, 2025, relating to the financial statements of Anika Therapeutics, Inc. and the effectiveness of Anika Therapeutics, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Anika Therapeutics, Inc. for the year ended December 31, 2024.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

November 5, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Anika Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | 2017 Omnibus Incentive Plan, as amended, Common stock, $0.01 par value per share | Other | 475000 | $9.775 | $4643125.00 | 0.0001381 | $641.22 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $4643125.00  |  | $641.22  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $641.22  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-8 shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act of 1933. The price per share and aggregate offering price are calculated on the basis of $9.775, average of the high and low prices of the Registrant's Common Stock as reported on the NASDAQ Global Select Market on October 31, 2025. (3) Represents an additional 475,000 shares of Common Stock issuable under the Plan. These 475,000 shares of Common Stock represent an increase in the number of shares of Common Stock reserved for issuance under the Plan, which increase was approved by the Registrant's stockholders on June 20, 2025, at the Registrant's 2025 Annual Meeting of Stockholders. Shares available for issuance under the Plan were previously registered on Prior Registration Statements.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---